国产99热精品_欧美疯狂做受xxxx猛交_婷婷在线网站_日韩无遮挡毛片_欧美高清momspuss_欧美激情福利

丹麥Santaris Pharma
Santaris Pharma是一家丹麥的臨床階段的生物制藥公司。公司成立于2003年，有著LNA技術(shù)的專利權(quán)LNA技術(shù)是第三代的反義核酸化學(xué)技術(shù)，用于開發(fā)新品種的RNA藥物，也稱RNA拮抗劑。Santaris Pharma已經(jīng)開發(fā)了mRNA拮抗劑和microRNA拮抗劑，用于沉默與各種疾病如癌癥、代謝紊亂、病毒感染相關(guān)的mRNA和microRNA。Santaris Pharma在2006年5月完成了第二階段四千萬歐元的融資，并在2007年12月第三階段融資兩千萬歐元。Santaris Pharma與新澤西的Enzon制藥公司有著全球合作，來開發(fā)和商業(yè)化一系列Santaris Pharma RNA拮抗劑，并與GlaxoSmithKline結(jié)成戰(zhàn)略同盟，開探索、開發(fā)和商業(yè)化針對(duì)病毒疾病的新型藥物。

Santaris Pharma is dedicated to the exciting new field of RNA-therapeutics, and is ready to deliver on the promise of the technology today. Our proprietary Locked Nucleic Acid Drug Platform and state-of-the-art Drug Discovery Engine are transforming the field of RNA-based medicines, making safe and effective modulation of disease-related RNAs an achievable goal.

The Company's drug development pipeline is focused on improving the treatment and outcome of patients with metabolic disorders and infectious diseases. In collaboration with our strategic partners, we are engaged in a broad array of additional therapeutic areas such as cancer, inflammatory diseases and rare genetic disorders.